BTOG 2022 | Deciphering an NGS report in lung cancer
Alastair Greystoke, PhD, MBChB, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, comments on how clinicians can understand a next-generation sequencing (NGS) report, which is often more comprehensive in terms of detecting a wide range of mutations. Initial interpretation of the report should include analysis of the ctDNA, as well as seeing how many driver mutations are present and if they are treatable. Prof. Greystoke additionally highlights various resources for healthcare professionals such as the Experimental Cancer Trial Finder (EC Trial Finder) created by Experimental Cancer Medicine Centres (ECMC). This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Prof. Greystoke reports consultancy and speaker fees from AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, MSD, Novartis, Pfizer, Lilly, Takeda and Roche; and research funding from AstraZeneca. He is also the clinical Lead for Cancer North East England Hull and Yorkshire Genomic Laboratory Hub and a member of the National Test Directory Evaluation Working Group.
